MedDataX Logo

Validity of Mediastinal Blood Pool SUV Ratio

NCT ID: NCT05258045

Last Updated: 2022-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

-Validity of blood pool SUV ratio in identification of malignancy in case of diseased liver.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PET/CT is the functional imaging tool that can measure increased glucose metabolism in cancer tissues by using flourine 18 FDG which is FDA approved and used routinely in identification of malignant lesions , staging and restaging of many malignancy like lymphoma, breast cancer, lung cancer and cancer colon.

In clinical routine, SUV is often used to determine the glucose metabolism in tumours by 18F-FDG PET/CT. And can be further normalised to SUVs in reference regions resulting in a SUV ratio (SUV ratio).in routine work SUV of the lesion is normalised to SUV of the liver , but this not used if the liver is diseased like as liver cirrhosis or liver metastases , so SUV ratio of lesion to mediastinal blood pool and SUV ratio of the lesion to liver will be measured in correlation to pathology to assess validity of SUV of mediastinal blood pool.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Validity of Blood Pool SUV Ratio in Identification of Malignancy in Case of Diseased Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SUV ratio of mediastinal blood pool to the lesion and SUV ratio of liver to lesion

Avidity of SUV of blood pool

F18 FDG

Intervention Type RADIATION

Radioactive material

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

F18 FDG

Radioactive material

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* This study will include cancer pt who did PET/CT scan who presented to nuclear medicine unit during the period from 2021 until the end of the study.

Exclusion Criteria

* Severely ill patient
* Pt with glucose level above 200
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zainab Fathy Mohammed

Resident doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zainab Fathy Mohammed, Resident doctor

Role: CONTACT

Phone: 01099024404

Email: [email protected]

Waleed Ahmed Diab, Assistant professor

Role: CONTACT

Phone: 01004242213

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PET/CT in malignancy

Identifier Type: -

Identifier Source: org_study_id